News + Font Resize -

Dabur OncQuest Receives NABL Accreditation
Our Bureau, New Delhi | Tuesday, September 19, 2006, 08:00 Hrs  [IST]

Dabur OncQuest, an offshoot of Dabur Pharma, which concentrates on Indian oncology medical testing market, has received National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation. The accreditation is in accordance with ISO 15189:2003 and is specific to medical testing laboratories. This accreditation is valid for the next two years. Dabur OncQuest is the only specialized oncology medical testing focus laboratory to receive this recognition.

OncQuest's new technologically advanced clinical and research laboratory is fully equipped with molecular technologies allowing for rapid advancement in the complex field of proteomics, genomics, and bioinformatics. OncQuest is one of its kind laboratories in South East Asia to have exclusively ventured in the area of Molecular Diagnostics & other advanced medical testing techniques. The new integrated research facility provides a strong foundation for Dabur OncQuest to grow within the field of genetic oncology. This laboratory is equipped to provide the most advanced proteins/antibodies and nucleic acid based diagnostic and prognostic tests for the better and more accurate diagnosis and management of cancer.

On receiving the accreditation, Vivek Trikha, Head-Diagnostics, Dabur OncQuest said, "We are happy to receive this recognition from the sole authority on medical Testing and Calibration in India. This accreditation has given an impetus to our mission of extending the survival and improving the quality of life of cancer patients by providing scientifically advanced, cost-effective molecular diagnostics tests,"

Dabur OncQuest had recently hosted a Doctors Conference in Kolkata on 'Recent Advancements in Cancer Diagnostics'. The conference was organized to discuss the growing importance of cancer diagnostics in the wake of increasing instances of the cancer in the country and to bring to the forefront initiatives in early diagnosis by Dabur OncQuest in this direction. Among the speakers were, Aditya C Burman, General Manager, Regional Head - Latin America, Dr Sarjana Dutt, Scientific Manager, Dabur OncQuest and Dr Ashish Mukherjee MD, DNB, DCH; Medical Director, Himadri Memorial Cancer Welfare Trust. The other eminent participants included Dr Moloy Ghosh, Dr Ujwal Mani, Dr Maitreyee Bhattarcharjee and Dr Utpal Choudhury.

Dabur has given impetus to devising sensitive tools & introduce new technologies for Screening, Diagnosis; Monitoring & Treatment of the disease in several gray areas in cancer biology. It has created a ' Centre of Excellence' in Diagnostic Oncology wherein 'State-of-the-art' technologies are centralized under one roof. OncQuest's new technologically advanced clinical and research laboratory is fully equipped with molecular technologies allowing for rapid advancement in the complex field of proteomics, genomics, and bioinformatics. OncQuest is one of its kind laboratories in South East Asia to have exclusively ventured in the area of Molecular Diagnostics & other advanced testing techniques.

Post Your Comment

 

Enquiry Form